Protocols

The available clinical trial evidence for NAD+ supplementation protocols is limited, with most studies focusing on NAD+ precursors rather than direct NAD+ administration.

NAD+ Precursor Supplementation

Nicotinamide Riboside (NR):

Clinical trials have investigated NR supplementation in heart failure patients (NCT03423342) and in combination with exercise interventions (NCT04907110)
Specific dosing protocols from these completed studies are not detailed in the available evidence

NAD Replenishment Therapy:

The ongoing NADAPT study (NCT06162013) is investigating NAD replenishment therapy for atypical Parkinsonism in a Phase 2 randomized, double-blind trial
Specific dosing protocols for this study are not provided in the available evidence

Evidence Limitations

The current literature search reveals significant gaps in published dosing and administration protocols for NAD+ supplementation. While multiple clinical trials have been conducted or are ongoing, the specific dosing regimens, administration routes, treatment durations, and safety monitoring protocols are not detailed in the available abstracts and trial registrations.

Most research appears to focus on NAD+ metabolism, enzymatic pathways, and therapeutic targets rather than standardized clinical protocols. The mechanistic studies examine NAD+ involvement in various disease processes including Alzheimer's disease, pulmonary fibrosis, and metabolic disorders, but do not provide clinical dosing guidance.

Important Medical Disclaimer

This information is for educational purposes only and does not constitute personalized medical advice. NAD+ supplementation protocols should only be determined and supervised by qualified healthcare providers who can assess individual patient needs, medical history, and potential drug interactions. Dosing, administration methods, and monitoring requirements must be individualized based on the specific clinical indication and patient factors.

NAD+

Member access required